No Data
Express News | Brainstorm Cell Therapeutics to Provide Corporate Mid-Year Update on Nurown Program
Brainstorm Cell Therptcs Entered Into Securities Purchase Agreement With a Single Institutional Investor >BCLI
Brainstorm Cell Therptcs Entered Into Securities Purchase Agreement With a Single Institutional Investor >BCLI
Express News | Brainstorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct Offering
Express News | Brainstorm Cell Therapeutics Inc - Alignment With FDA on Nur Own Cmc Aspects
Express News | Brainstorm Cell Therapeutics Reaches Alignment With FDA on Cmc Aspects of Phase 3B Nurown® Clinical Trial
BrainStorm Appoints Haro Hartounian as COO